Search Results

There are 4346 results for: content related to: Prolonged 18 FDG-PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor (Rd-G)

  1. You have free access to this content
    Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression

    British Journal of Haematology

    Volume 160, Issue 4, February 2013, Pages: 487–502, Ling-Hua Zhang, Jolanta Kosek, Maria Wang, Carla Heise, Peter H. Schafer and Rajesh Chopra

    Version of Record online : 18 DEC 2012, DOI: 10.1111/bjh.12172

  2. You have free access to this content
    Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion

    British Journal of Haematology

    Volume 166, Issue 2, July 2014, Pages: 189–201, Joaquín Sánchez-García, Consuelo del Cañizo, Ignacio Lorenzo, Benet Nomdedeu, Elisa Luño, Raquel de Paz, Blanca Xicoy, David Valcárcel, Salut Brunet, Victor Marco-Betes, Marta García-Pintos, Santiago Osorio, Mar Tormo, Alicia Bailén, Carlos Cerveró, Fernando Ramos, María Diez-Campelo, Esperanza Such, Beatriz Arrizabalaga, Gemma Azaceta, Joan Bargay, María J. Arilla, José Falantes, Josefina Serrano-López, Guillermo F. Sanz and forthe Spanish Group on Myelodysplastic Syndromes (GES MD)

    Version of Record online : 9 APR 2014, DOI: 10.1111/bjh.12876

  3. You have free access to this content
    Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients

    Clinical & Experimental Immunology

    Volume 177, Issue 2, August 2014, Pages: 439–453, A. Busch, D. Zeh, V. Janzen, L.-O. Mügge, D. Wolf, L. Fingerhut, C. Hahn-Ast, O. Maurer, P. Brossart and M. von Lilienfeld-Toal

    Version of Record online : 9 JUL 2014, DOI: 10.1111/cei.12343

  4. You have free access to this content
    Lenalidomide in multiple myeloma: Current status and future potential

    American Journal of Hematology

    Volume 87, Issue 12, December 2012, Pages: 1089–1095, Hang Quach, Anna Kalff and Andrew Spencer

    Version of Record online : 28 MAY 2012, DOI: 10.1002/ajh.23234

  5. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo

    The Prostate

    Volume 72, Issue 8, 1 June 2012, Pages: 856–867, J.Y. Henry, L. Lu, M. Adams, B. Meyer, J.B. Bartlett, Prof. A.G. Dalgleish and C. Galustian

    Version of Record online : 3 OCT 2011, DOI: 10.1002/pros.21488

  6. You have free access to this content
    Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response

    British Journal of Haematology

    Volume 154, Issue 3, August 2011, Pages: 325–336, Antonia Lopez-Girona, Daniel Heintel, Ling-Hua Zhang, Derek Mendy, Svetlana Gaidarova, Helen Brady, Justin Blake Bartlett, Peter H. Schafer, Martin Schreder, Arnold Bolomsky, Bernadette Hilgarth, Niklas Zojer, Heinz Gisslinger, Heinz Ludwig, Tom Daniel, Ulrich Jäger and Rajesh Chopra

    Version of Record online : 24 JUN 2011, DOI: 10.1111/j.1365-2141.2011.08689.x

  7. You have free access to this content
    Short-Term Lenalidomide (Revlimid) Administration Ameliorates Cardiomyocyte Contractile Dysfunction in ob/ob Obese Mice


    Volume 20, Issue 11, November 2012, Pages: 2174–2185, Linlin Li, Yinan Hua, Maolong Dong, Quan Li, Derek T. Smith, Ming Yuan, Kyla R. Jones and Jun Ren

    Version of Record online : 31 DEC 2012, DOI: 10.1038/oby.2012.106

  8. Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels

    European Journal of Haematology

    Volume 91, Issue 6, December 2013, Pages: 504–513, Alexandra J. Greenberg, Denise K. Walters, Shaji K. Kumar, S. Vincent Rajkumar and Diane F. Jelinek

    Version of Record online : 17 SEP 2013, DOI: 10.1111/ejh.12192

  9. You have free access to this content
    Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response

    British Journal of Haematology

    Volume 155, Issue 4, November 2011, Pages: 457–467, Asher A. Chanan-Khan, Kasyapa Chitta, Noreen Ersing, Aneel Paulus, Aisha Masood, Taimur Sher, Abhisek Swaika, Paul K. Wallace, Terry L. Mashtare Jr, Greg Wilding, Kelvin Lee, Myron S. Czuczman, Ivan Borrello and Naveen Bangia

    Version of Record online : 20 OCT 2011, DOI: 10.1111/j.1365-2141.2011.08882.x

  10. Evaluation of the developmental toxicity of lenalidomide in rabbits

    Birth Defects Research Part B: Developmental and Reproductive Toxicology

    Volume 80, Issue 3, June 2007, Pages: 188–207, Mildred S. Christian, Oscar L. Laskin, Valerie Sharper, Alan Hoberman, David I. Stirling and Louise Latriano

    Version of Record online : 14 JUN 2007, DOI: 10.1002/bdrb.20115

  11. You have full text access to this OnlineOpen article
    Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

    European Journal of Haematology

    Volume 93, Issue 5, November 2014, Pages: 429–438, Aristoteles Giagounidis, Ghulam J. Mufti, Moshe Mittelman, Guillermo Sanz, Uwe Platzbecker, Petra Muus, Dominik Selleslag, Odile Beyne-Rauzy, Peter te Boekhorst, Consuelo del Cañizo, Agnès Guerci-Bresler, Lars Nilsson, Michael Lübbert, Bruno Quesnel, Arnold Ganser, David Bowen, Brigitte Schlegelberger, Gudrun Göhring, Tommy Fu, Bouchra Benettaib, Eva Hellström-Lindberg and Pierre Fenaux

    Version of Record online : 9 JUN 2014, DOI: 10.1111/ejh.12380

  12. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma

    British Journal of Haematology

    Volume 172, Issue 6, March 2016, Pages: 889–901, Emily Rychak, Derek Mendy, Tao Shi, Yuhong Ning, Jim Leisten, Ling Lu, Karen Miller, Rama K. Narla, Robert Z. Orlowski, Heather K. Raymon, Chad C. Bjorklund, Anjan Thakurta, Anita K. Gandhi, Brian E. Cathers, Rajesh Chopra, Thomas O. Daniel and Antonia Lopez-Girona

    Version of Record online : 23 FEB 2016, DOI: 10.1111/bjh.13905

  13. You have full text access to this OnlineOpen article
    Lenalidomide at Therapeutic and Supratherapeutic Doses Does Not Prolong QTc Intervals in the Thorough QTc Study Conducted in Healthy Men

    Basic & Clinical Pharmacology & Toxicology

    Volume 113, Issue 3, September 2013, Pages: 179–186, Nianhang Chen, Ying Ye, Liangang Liu, Josephine Reyes, Mahmoud S. Assaf, Claudia Kasserra, Simon Zhou and Maria Palmisano

    Version of Record online : 20 JUN 2013, DOI: 10.1111/bcpt.12081

    Corrected by:

    Erratum: Erratum

    Vol. 113, Issue 5, 361, Version of Record online: 7 OCT 2013

  14. You have full text access to this OnlineOpen article
    Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN

    British Journal of Haematology

    Volume 164, Issue 6, March 2014, Pages: 811–821, Anita K. Gandhi, Jian Kang, Courtney G. Havens, Thomas Conklin, Yuhong Ning, Lei Wu, Takumi Ito, Hideki Ando, Michelle F. Waldman, Anjan Thakurta, Anke Klippel, Hiroshi Handa, Thomas O. Daniel, Peter H. Schafer and Rajesh Chopra

    Version of Record online : 13 DEC 2013, DOI: 10.1111/bjh.12708

  15. Pharmacokinetics of Lenalidomide in Subjects With Various Degrees of Renal Impairment and in Subjects on Hemodialysis

    The Journal of Clinical Pharmacology

    Volume 47, Issue 12, December 2007, Pages: 1466–1475, Nianhang Chen, Henry Lau, Linghui Kong, Gondi Kumar, Jerom B. Zeldis, Robert Knight and Osca L. Laskin

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007309563

  16. You have free access to this content
    Guidelines for the diagnosis and management of multiple myeloma 2011

    British Journal of Haematology

    Volume 154, Issue 1, July 2011, Pages: 32–75, Jennifer M. Bird, Roger G. Owen, Shirley D’Sa, John A. Snowden, Guy Pratt, John Ashcroft, Kwee Yong, Gordon Cook, Sylvia Feyler, Faith Davies, Gareth Morgan, Jamie Cavenagh, Eric Low, Judith Behrens and on behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum

    Version of Record online : 14 MAY 2011, DOI: 10.1111/j.1365-2141.2011.08573.x

  17. Initial testing of lenalidomide by the pediatric preclinical testing program

    Pediatric Blood & Cancer

    Volume 57, Issue 4, October 2011, Pages: 606–611, C. Patrick Reynolds, Min H. Kang, Stephen T. Keir, Richard Gorlick, E. Anders Kolb, Richard Lock, John M. Maris, Hernan Carol, Christopher L. Morton, Catherine A. Billups, Malcolm A. Smith and Peter J. Houghton

    Version of Record online : 25 FEB 2011, DOI: 10.1002/pbc.22877

  18. Tumour necrosis factor-α inhibition with lenalidomide alleviates tissue oxidative injury and apoptosis in ob/ob obese mice

    Clinical and Experimental Pharmacology and Physiology

    Volume 41, Issue 7, July 2014, Pages: 489–501, Xiaoling Zhu, Shasha Jiang, Nan Hu, Fuling Luo, Hailong Dong, Yu-Ming Kang, Kyla R Jones, Yunzeng Zou, Lize Xiong and Jun Ren

    Version of Record online : 8 JUL 2014, DOI: 10.1111/1440-1681.12240

  19. You have free access to this content
    United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma

    International Journal of Laboratory Hematology

    Volume 31, Issue 2, April 2009, Pages: 119–131, F. DAVIES, C. MORRIS, J. BIRD, G. COOK, C. WILLIAMS, J. TIGHE, J. CAVENAGH, J. BEHRENS, S. SCHEY, G. MORGAN and On Behalf Of The United Kingdom Myeloma Forum

    Version of Record online : 4 NOV 2008, DOI: 10.1111/j.1751-553X.2008.01106.x

  20. You have free access to this content
    Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner

    British Journal of Haematology

    Volume 157, Issue 1, April 2012, Pages: 59–66, Aisha Masood, Kasyapa Chitta, Aneel Paulus, A. Nazmul H. Khan, Taimur Sher, Noreen Ersing, Kena C. Miller, Deborah Manfredi, Sikander Ailawadhi, Ivan Borrelo, Kelvin P. Lee and Asher Chanan-Khan

    Version of Record online : 15 DEC 2011, DOI: 10.1111/j.1365-2141.2011.08984.x